BioCrude Technologies USA, Inc. financial data

Location
1255 Phillips Square, Suite 605, Montreal, Quebec, Canada
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.21 % -36.6%
Debt-to-equity -109 % +5.06%
Return On Equity 108 % -9.12%
Return On Assets -813 % +14.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.9M shares +0.01%
Common Stock, Shares, Outstanding 50.9M shares +0.01%
Entity Public Float 0 USD
Common Stock, Value, Issued 50.9K USD +0.01%
Weighted Average Number of Shares Outstanding, Basic 50.8M shares +0%
Weighted Average Number of Shares Outstanding, Diluted 50.8M shares +0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 190K USD -29.9%
Operating Income (Loss) -190K USD +29.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -198K USD +27.9%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 196 USD -99.4%
Property, Plant and Equipment, Net 11.5K USD -23.3%
Assets 11.7K USD -76.9%
Liabilities, Current 421K USD +52.2%
Liabilities 421K USD +52.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 27.1K USD -5.41%
Retained Earnings (Accumulated Deficit) -9.59M USD -2.11%
Stockholders' Equity Attributable to Parent -406K USD -82.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -303K USD -27.3%
Liabilities and Equity 11.7K USD -76.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.1K USD +62%
Net Cash Provided by (Used in) Financing Activities 30.1K USD -62.1%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 50.9M shares +0.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26K USD -1550%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 196 USD -23.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 476K USD +13.9%
Depreciation 1.21K USD +11.9%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47.2K USD +26.8%
Property, Plant and Equipment, Gross 37.4K USD +3.64%
Additional Paid in Capital 9.1M USD +0.18%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 8.29K USD +126%